PharmNovo aims to change the lives of people suffering from chronic pain

Patients with neuropathic pain are a growing population facing increasingly challenging conditions. Finding a safe and effective way to help those patients has always been the Holy Grail to PharmNovo’s founder Bengt von Mentzer. PharmNovo’s promising drug candidate PN6047 will shortly be entering phase II proof-of-concept studies. »

Making a difference to women worldwide

Gedea Biotech has developed the world’s first antibiotic-free treatment to both treat and prevent bacterial vaginosis. The treatment is called pHyph, and is a vaginal tablet that has shown a medical effectiveness in treating bacterial vaginosis in line with antibiotics on the market, but with a superior safety profile and lower risk of recurrence. »

Does the world need prebiotics?

The gut and skin microbiome eco-systems are among the most complex setups in the world. By decoding and analysing them, it is possible to understand why some diseases are more developed in some individuals and not in others. More importantly, it is possible to present solutions to prevent the development of any disease in the […] »